Cargando…
g-Nomic: a new pharmacogenetics interpretation software
We present g-Nomic, a pharmacogenetics interpretation software that analyzes globally a prescribed medication taking into account the personal background genetics, drug–drug interactions, lifestyle, nutritional supplements, inhibitors, inducers, and other risks to analyze primary or secondary metabo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554524/ https://www.ncbi.nlm.nih.gov/pubmed/31239753 http://dx.doi.org/10.2147/PGPM.S203585 |
_version_ | 1783424982177546240 |
---|---|
author | Sabater, Ana Ciudad, Carlos J Cendros, Marc Dobrokhotov, Denis Sabater-Tobella, Juan |
author_facet | Sabater, Ana Ciudad, Carlos J Cendros, Marc Dobrokhotov, Denis Sabater-Tobella, Juan |
author_sort | Sabater, Ana |
collection | PubMed |
description | We present g-Nomic, a pharmacogenetics interpretation software that analyzes globally a prescribed medication taking into account the personal background genetics, drug–drug interactions, lifestyle, nutritional supplements, inhibitors, inducers, and other risks to analyze primary or secondary metabolism pathways. G-Nomic provides a set of recommendations describing the suitability of a given combination of drugs for each patient according to their genes and polymedication. G-Nomic is updated monthly including data from the new drugs to be included, their known interactions, and the relevant pharmacokinetic biomarkers. For the interactions, the list is curated manually, only keeping those with clinical relevance. For each drug, their FDA and EMA drug labels are accessed, to check for relevant enzymes and transport proteins that influence its pharmacokinetics, and for their ability to induce or inhibit other enzymes, particularly the CYP-450 system. When this information is not available, a PubMed search is made to look for these characteristics. In addition, a distinction is made between drugs and prodrugs. A query on the g-Nomic software begins with entering the medication by either their common or commercial name. Non-pharmacological substances can be also added or selected under “lifestyle habits”. The lifestyle list is dynamic, showing only the substances known to interact with the drugs that are currently selected, and includes herb compounds, such as St. John’s wort, as well as proper lifestyle substances such as grapefruit or cigarette smoking. The software provides a list of the genes classified as primary biomarkers as candidates for genetic testing, and a list of the interactions that have been detected. If genetic information is available then, or is made available at a later point, these results can also be entered and the software returns pharmacogenetics recommendations regarding specific genotypes. g-Nomic takes all the above-mentioned parameters in an easy and user-friendly tool making prescription safer. |
format | Online Article Text |
id | pubmed-6554524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65545242019-06-25 g-Nomic: a new pharmacogenetics interpretation software Sabater, Ana Ciudad, Carlos J Cendros, Marc Dobrokhotov, Denis Sabater-Tobella, Juan Pharmgenomics Pers Med Methodology We present g-Nomic, a pharmacogenetics interpretation software that analyzes globally a prescribed medication taking into account the personal background genetics, drug–drug interactions, lifestyle, nutritional supplements, inhibitors, inducers, and other risks to analyze primary or secondary metabolism pathways. G-Nomic provides a set of recommendations describing the suitability of a given combination of drugs for each patient according to their genes and polymedication. G-Nomic is updated monthly including data from the new drugs to be included, their known interactions, and the relevant pharmacokinetic biomarkers. For the interactions, the list is curated manually, only keeping those with clinical relevance. For each drug, their FDA and EMA drug labels are accessed, to check for relevant enzymes and transport proteins that influence its pharmacokinetics, and for their ability to induce or inhibit other enzymes, particularly the CYP-450 system. When this information is not available, a PubMed search is made to look for these characteristics. In addition, a distinction is made between drugs and prodrugs. A query on the g-Nomic software begins with entering the medication by either their common or commercial name. Non-pharmacological substances can be also added or selected under “lifestyle habits”. The lifestyle list is dynamic, showing only the substances known to interact with the drugs that are currently selected, and includes herb compounds, such as St. John’s wort, as well as proper lifestyle substances such as grapefruit or cigarette smoking. The software provides a list of the genes classified as primary biomarkers as candidates for genetic testing, and a list of the interactions that have been detected. If genetic information is available then, or is made available at a later point, these results can also be entered and the software returns pharmacogenetics recommendations regarding specific genotypes. g-Nomic takes all the above-mentioned parameters in an easy and user-friendly tool making prescription safer. Dove 2019-05-29 /pmc/articles/PMC6554524/ /pubmed/31239753 http://dx.doi.org/10.2147/PGPM.S203585 Text en © 2019 Sabater et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Methodology Sabater, Ana Ciudad, Carlos J Cendros, Marc Dobrokhotov, Denis Sabater-Tobella, Juan g-Nomic: a new pharmacogenetics interpretation software |
title | g-Nomic: a new pharmacogenetics interpretation software |
title_full | g-Nomic: a new pharmacogenetics interpretation software |
title_fullStr | g-Nomic: a new pharmacogenetics interpretation software |
title_full_unstemmed | g-Nomic: a new pharmacogenetics interpretation software |
title_short | g-Nomic: a new pharmacogenetics interpretation software |
title_sort | g-nomic: a new pharmacogenetics interpretation software |
topic | Methodology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554524/ https://www.ncbi.nlm.nih.gov/pubmed/31239753 http://dx.doi.org/10.2147/PGPM.S203585 |
work_keys_str_mv | AT sabaterana gnomicanewpharmacogeneticsinterpretationsoftware AT ciudadcarlosj gnomicanewpharmacogeneticsinterpretationsoftware AT cendrosmarc gnomicanewpharmacogeneticsinterpretationsoftware AT dobrokhotovdenis gnomicanewpharmacogeneticsinterpretationsoftware AT sabatertobellajuan gnomicanewpharmacogeneticsinterpretationsoftware |